Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Wearable Device-Based Long-Term Management of Coronary Artery Disease: The OPPO-WATCH Study

NCT07912671 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07912671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Wearable Device-Based Long-Term Management of Coronary Artery Disease: The OPPO-WATCH Study
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2028
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic coronary syndrome

Arms

As registered; 2 arms.

  • Wearable Device-Based Management Group ExperimentalWearable Device-Based Monitoring and LE8 Feedback

    Participants receive wearable device-based, LE8-guided management with access to their monitoring data, health and medication reminders, and individualized LE8 score feedback, together with routine in-person cardiology outpatient follow-up every three months for 12 months.

  • Data-Blinded Wearable Monitoring Group Active comparatorRoutine Outpatient Care With Data-Blinded Wearable Monitoring

    Participants wear a smartwatch for data collection but do not have access to monitoring data, health or medication reminders, or Life's Essential 8 (LE8) score feedback. They receive routine in-person cardiology outpatient follow-up every three months for 12 months.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Life's Essential 8 (LE8) Cardiovascular Health Score From baseline through 12 months

    The primary outcome is the between-group difference in the change in the American Heart Association's Life's Essential 8 (LE8) cardiovascular health score from baseline to 12 months. The LE8 score is calculated automatically by the cloud-based system using data on eight cardiovascular health components: physical activity, sleep health, nicotine exposure, diet, blood pressure, blood glucose, blood lipids, and body mass index. Each component is scored from 0 to 100, and the overall LE8 score is calculated as the unweighted average of the eight component scores, ranging from 0 to 100. Higher scores indicate better cardiovascular health.

Lead sponsor's other trials

China National Center for Cardiovascular Diseases, most recent start first.

Similar trials

Same condition (Coronary Disease) and phase, most recent start first.